RGC Stock Overview
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Regencell Bioscience Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.35 |
| 52 Week High | US$30.49 |
| 52 Week Low | US$3.16 |
| Beta | -0.35 |
| 1 Month Change | 55.07% |
| 3 Month Change | -34.76% |
| 1 Year Change | -79.46% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.05% |
Recent News & Updates
Shareholder Returns
| RGC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.5% | -0.6% | 1.0% |
| 1Y | -79.5% | 10.6% | 21.9% |
Return vs Industry: RGC underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: RGC underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| RGC volatility | |
|---|---|
| RGC Average Weekly Movement | 20.3% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGC's share price has been volatile over the past 3 months.
Volatility Over Time: RGC's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12 | Yat-Gai Au | www.regencellbioscience.com |
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Holdings Limited Fundamentals Summary
| RGC fundamental statistics | |
|---|---|
| Market cap | US$69.62m |
| Earnings (TTM) | -US$5.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.9x
P/E RatioIs RGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.87m |
| Earnings | -US$5.87m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RGC perform over the long term?
See historical performance and comparison